NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $233.88 million. The enterprise value is $247.90 million.
| Market Cap | 233.88M |
| Enterprise Value | 247.90M |
Important Dates
The last earnings date was Wednesday, May 8, 2024, after market close.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 28.77 million shares outstanding. The number of shares has increased by 12.70% in one year.
| Shares Outstanding | 28.77M |
| Shares Change (YoY) | +12.70% |
| Shares Change (QoQ) | +5.50% |
| Owned by Insiders (%) | 4.26% |
| Owned by Institutions (%) | 78.38% |
| Float | 11.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.39 |
| Forward PS | 2.96 |
| PB Ratio | 16.31 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.43, with a Debt / Equity ratio of 5.10.
| Current Ratio | 6.43 |
| Quick Ratio | 5.39 |
| Debt / Equity | 5.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.58 |
Financial Efficiency
Return on equity (ROE) is -173.60% and return on invested capital (ROIC) is -30.20%.
| Return on Equity (ROE) | -173.60% |
| Return on Assets (ROA) | -30.90% |
| Return on Capital (ROIC) | -30.20% |
| Revenue Per Employee | $403,936 |
| Profits Per Employee | -$184,246 |
| Employee Count | 171 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 1.62 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +90.00% in the last 52 weeks. The beta is 2.07, so NeuroPace's price volatility has been higher than the market average.
| Beta (1Y) | 2.07 |
| 52-Week Price Change | +90.00% |
| 50-Day Moving Average | 12.90 |
| 200-Day Moving Average | 10.46 |
| Relative Strength Index (RSI) | 27.06 |
| Average Volume (30 Days) | 122,182 |
Short Selling Information
The latest short interest is 89,808, so 0.31% of the outstanding shares have been sold short.
| Short Interest | 89,808 |
| Short Previous Month | 97,143 |
| Short % of Shares Out | 0.31% |
| Short % of Float | 0.77% |
| Short Ratio (days to cover) | 0.72 |
Income Statement
In the last 12 months, NeuroPace had revenue of $69.07 million and -$31.51 million in losses. Loss per share was -$1.18.
| Revenue | 69.07M |
| Gross Profit | 51.09M |
| Operating Income | -26.40M |
| Pretax Income | -31.51M |
| Net Income | -31.51M |
| EBITDA | -21.06M |
| EBIT | -22.70M |
| Loss Per Share | -$1.18 |
Balance Sheet
The company has $59.07 million in cash and $73.09 million in debt, giving a net cash position of -$14.02 million or -$0.49 per share.
| Cash & Cash Equivalents | 59.07M |
| Total Debt | 73.09M |
| Net Cash | -14.02M |
| Net Cash Per Share | -$0.49 |
| Equity / Book Value | 14.34M |
| Book Value Per Share | 0.50 |
| Working Capital | 71.14M |
Cash Flow
In the last 12 months, operating cash flow was -$17.53 million and capital expenditures -$145,000, giving a free cash flow of -$17.68 million.
| Operating Cash Flow | -17.53M |
| Capital Expenditures | -145,000 |
| Free Cash Flow | -17.68M |
| FCF Per Share | -$0.63 |
Margins
Gross margin is 73.97%, with operating and profit margins of -38.22% and -45.61%.
| Gross Margin | 73.97% |
| Operating Margin | -38.22% |
| Pretax Margin | -45.61% |
| Profit Margin | -45.61% |
| EBITDA Margin | -30.49% |
| EBIT Margin | -32.86% |
| FCF Margin | -25.59% |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.70% |
| Shareholder Yield | -12.70% |
| Earnings Yield | -13.47% |
| FCF Yield | -7.56% |
Analyst Forecast
The average price target for NeuroPace is $17.00, which is 108.08% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.00 |
| Price Target Difference | 108.08% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 26.48% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -4.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.8 |
| Piotroski F-Score | 3 |